OncoRat® featured in Clinical Cancer Research for prostate cancer studies

November 6th, 2019|Comments Off on OncoRat® featured in Clinical Cancer Research for prostate cancer studies

Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems: A case study of SRG OncoRat tumor xenografts from a Clinical Cancer Research publication (post download) (Paper download)  Bridging the ‘valley of death’ in oncology clinical trials: While [...]

The OncoRat® is the ideal host for patient-derived xenografts of ovarian cancer cells

December 11th, 2018|Comments Off on The OncoRat® is the ideal host for patient-derived xenografts of ovarian cancer cells

Ovarian cancer is the most lethal gynecological cancer in the United States. Advances in cytotoxic, platinum-based chemotherapeutics combined with tumor resection surgery allows approximately 80% of these patients to achieve remission. Unfortunately, the vast majority [...]

Evolution of the rat model

November 16th, 2018|Comments Off on Evolution of the rat model

Rats have been favored for drug development studies because the metabolism and pharmacokinetic properties of drugs in rats are most similar to humans. Rats are also preferable for xenograft studies because they allow for tumor [...]

H358 NSCLC xenografts in humanized rats: the ideal in vivo model for studying KRAS mutations

October 20th, 2018|Comments Off on H358 NSCLC xenografts in humanized rats: the ideal in vivo model for studying KRAS mutations

Lung adenocarcinomas, the major histological subtype of non-small cell lung cancers (NSCLC), harbor oncogenic KRAS mutations in approximately 25% of cases. Many of the targeted therapies that have been studied and approved for the treatment [...]

Hera Biolabs announces Molecular Cancer Therapeutics publication on immunodeficient rats for oncology research

October 19th, 2018|Comments Off on Hera Biolabs announces Molecular Cancer Therapeutics publication on immunodeficient rats for oncology research

Hera Biolabs, the University of Michigan, Case Western Reverse University and other collaborators are announcing a recent publication in the American Association for Cancer Research (AACR) journal, Molecular Cancer Therapeutics, entitled, "Sprague Dawley Rag2-null rats [...]

Breakthroughs in gene editing allows for the creation of superior preclinical oncology models

September 30th, 2018|Comments Off on Breakthroughs in gene editing allows for the creation of superior preclinical oncology models

Gene editing is getting a lot of attention in the oncology field for its potential in gene therapy, but this only scratches the surface of its potential applications. Hera is now using it to fight [...]

The OncoRat®: Hosting valuable tumor xenograft models that are difficult or impossible to study using in vitro or mouse models

September 18th, 2018|Comments Off on The OncoRat®: Hosting valuable tumor xenograft models that are difficult or impossible to study using in vitro or mouse models

One of the most widely used methods of modeling human tumor biology for preclinical research is the use of xenografts. Xenografts are generated by implanting human tumor cells under the skin or directly into the [...]

Patient derived xenograft studies from wider varieties of patient sub-populations promise improved clinical trial selection and design

August 9th, 2018|Comments Off on Patient derived xenograft studies from wider varieties of patient sub-populations promise improved clinical trial selection and design

Around 85% of preclinical drugs entering clinical trials in oncology never make it past Phase 1 because they fail to demonstrate sufficient efficacy due to testing in unselected patient populations 1-3. Many of these failed [...]

OncoRat® PDX models highlighted in Drug Discovery News (DDN) Special Report on Cancer: Aiming for Avatars

July 18th, 2018|Comments Off on OncoRat® PDX models highlighted in Drug Discovery News (DDN) Special Report on Cancer: Aiming for Avatars

While advances in in-vitro platforms have allowed researchers to better visually monitor a variety of aspects of tumor biology, a significant limitation of 3D cultured models for patient therapeutic monitoring or “patient avatars” is the [...]

Hera Biolabs to present at the 2018 AACR Annual Meeting.

April 12th, 2018|Comments Off on Hera Biolabs to present at the 2018 AACR Annual Meeting.

Hera Biolabs will be presenting xenograft, PDX, and humanization of the immune system data from our new immunodeficient OncoRat SRG model at the up coming AACR 2018 Annual Meeting.   POSTER: Title: The SRG Rat™: A [...]

By |September 5th, 2016                                                                                                                Read More